Recently, several retrospective, unplanned analyses examined primary tumor sidedness and revealed that anti-EGFR therapy clearly benefitted patients with LCRC, whereas patients with RCRC derived limited benefit [15-17]. This evidence concerns the gene EGFR and neoplasm.